NCT00531544已完成不适用
A SU011248 Expanded Access Protocol for Metastatic RCC Patients Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 350
- 试验地点
- 1
- 主要终点
- Efficacy
研究概览
简要总结
A SU011248 expanded access protocol for systemic therapy of patients with metastatic Renal Cell Carcinoma who are ineligible for participation in other SU011248 protocols but may derive benefit from treatment with SU011248
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic Renal Cell Carcinoma who are ineligible for participation in other SU011248 protocols but may derive benefit from treatment with SU011248
排除标准
- 未提供
结局指标
主要结局
Efficacy
时间窗: 2001-2012
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Approved For Marketing
不适用
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell CarcinomaCarcinoma, Renal CellNCT00130897Pfizer
终止
2 期
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersMetastatic Renal Cell CarcinomaMetastatic Urothelial CarcinomaNCT03115801Weill Medical College of Cornell University6
No Longer Available
不适用
Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell CarcinomaNCT03896815Incyte Corporation
已完成
3 期
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell CarcinomaCarcinoma, Renal CellNCT00111020Bayer2,567
No Longer Available
不适用
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)MelanomaNCT02083484Merck Sharp & Dohme LLC